Suppr超能文献

II期精原细胞瘤:为何化疗应维持为标准治疗方案。

Stage II Seminoma: Why Chemotherapy Should Remain a Standard.

作者信息

Naoun Natacha, Bernard-Tessier Alice, Fizazi Karim

机构信息

Department of Cancer Medicine, Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.

出版信息

Eur Urol Open Sci. 2023 Jan 28;49:69-70. doi: 10.1016/j.euros.2022.06.010. eCollection 2023 Mar.

Abstract

Chemotherapy (three cycles of bleomycin + etoposide + cisplatin or four of etoposide + cisplatin) cures the vast majority of stage II seminomas. Retroperitoneal lymph node dissection (RPLND) is safe in early-stage seminoma, but the risk of relapse is not negligible. Long-term chemotherapy side effects are a reality but may be reduced using de-escalation strategies such as in the SEMITEP trial design, motivated by growing interest in survivorship. RPLND may be an option for well-informed select patients who understand that it may be associated with a higher rate of relapse than with cisplatin-based chemotherapy. In any case, local and systemic treatment should not be performed outside high-volume centers.

摘要

化疗(博来霉素+依托泊苷+顺铂三个周期或依托泊苷+顺铂四个周期)可治愈绝大多数II期精原细胞瘤。腹膜后淋巴结清扫术(RPLND)在早期精原细胞瘤中是安全的,但复发风险并非可以忽略不计。长期化疗副作用是现实存在的,但可以通过采用降阶梯策略来降低,比如在SEMITEP试验设计中,这是出于对生存质量关注度的不断提高。对于充分知情且理解RPLND可能比基于顺铂的化疗有更高复发率的特定患者,RPLND可能是一种选择。无论如何,局部和全身治疗不应在非高容量中心进行。

相似文献

1
Stage II Seminoma: Why Chemotherapy Should Remain a Standard.
Eur Urol Open Sci. 2023 Jan 28;49:69-70. doi: 10.1016/j.euros.2022.06.010. eCollection 2023 Mar.
2
Retroperitoneal lymph node dissection for testicular seminomas: population-based practice and survival outcomes.
World J Urol. 2018 Jan;36(1):73-78. doi: 10.1007/s00345-017-2099-0. Epub 2017 Oct 12.
3
Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice.
Ther Adv Urol. 2012 Aug;4(4):187-205. doi: 10.1177/1756287212443170.
5
Primary and Postchemotherapy Retroperitoneal Lymphadenectomy for Testicular Cancer.
Oncol Res Treat. 2018;41(6):370-378. doi: 10.1159/000489508. Epub 2018 May 17.
10
Testicular cancer.
Curr Probl Cancer. 1998 Jul-Aug;22(4):187-274. doi: 10.1016/s0147-0272(98)90012-5.

引用本文的文献

3
Stage II Seminoma: Is There Something New on the Horizon?
Eur Urol Open Sci. 2023 Jan 30;49:78-79. doi: 10.1016/j.euros.2023.01.007. eCollection 2023 Mar.

本文引用的文献

2
Testicular seminoma and non-seminoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.
Ann Oncol. 2022 Apr;33(4):362-375. doi: 10.1016/j.annonc.2022.01.002. Epub 2022 Jan 19.
3
Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium.
J Clin Oncol. 2021 May 10;39(14):1563-1574. doi: 10.1200/JCO.20.03296. Epub 2021 Apr 6.
4
Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
CA Cancer J Clin. 2021 May;71(3):209-249. doi: 10.3322/caac.21660. Epub 2021 Feb 4.
5
Clinical utility of plasma miR-371a-3p in germ cell tumors.
J Cell Mol Med. 2019 Feb;23(2):1128-1136. doi: 10.1111/jcmm.14013. Epub 2018 Dec 7.
9
Stage II testicular seminoma: patterns of recurrence and outcome of treatment.
Eur Urol. 2004 Jun;45(6):754-59; discussion 759-60. doi: 10.1016/j.eururo.2004.01.020.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验